Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

• Status: Terminated
• Trial end date: 2015-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the effectiveness and safety of pasireotide long-acting release in patients who have rare tumors of neuroendocrine origin.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Pasireotide; Somatostatin

Criteria

Inclusion Criteria:

• Male and Female Patients at least 18 years old

• Patient who have rare tumors of neuroendocrine origin, such as tumors of the:

1. pancreas

2. pituitary glands

3. Nelson syndrome

4. ectopic-ACTH secreting tumor

• Patients who have failed standard of care treatment or for whom no standard of care treatment exist

• Signed Informed Consent

Exclusion Criteria:

• Patients with active gallbladder disease

• Patients with any ongoing or planned anti-neoplastic or interferon therapy

• Poorly controlled diabetes mellitus

• Female patients who are pregnant or lactating, or are of childbearing potential and not practicing a medically acceptable method of birth control

Other protocol-defined inclusion/exclusion criteria may apply.